Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Neoplasms 3 Non Small Cell Lung Carcinoma NSCLC 2 NSCLC 2 Melanoma 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Primary Breast Cancer 1 Non-Small Cell Lung Cancer With HER2- Mutations 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Carcinoma 1

Interventions

Paclitaxel 23 Carboplatin 22 Capecitabine 18 Gemcitabine 16 130-nm albumin-bound paclitaxel 16 pembrolizumab 14 Cyclophosphamide 12 atezolizumab 9 Epirubicin 9 sacituzumab govitecan 8 Albumin-Bound Paclitaxel 8 eribulin 6 Vinorelbine 6 Drug Therapy 6 Doxorubicin 6 camrelizumab 4 Docetaxel 4 Cisplatin 4 Injections 3 pegfilgrastim 2 olaparib 2 famitinib 2 Filgrastim 2 Everolimus 2 veliparib 1 trilaciclib 1 toripalimab 1 taxane 1 niraparib 1 ipatasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Triple Negative Breast Neoplasms × CP protocol × Clear all

NCT03168880 2025-04-09

TNBC

Tata Memorial Hospital

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡